
Generic competition expected to be strong as many small-molecule drug brands face patent expirations
Small-molecule drugs in the United States will experience the greatest degree of brand erosion as patents of many of the most popular drugs expire during the next several years, leaving them exposed to generic competition, according to a report published by Datamonitor.






















































































































































